Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Operations for 11 consecutive years, with 30843000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Operations rose 41.35% to 30843000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 179616000.0 through Sep 2025, up 1.18% year-over-year, with the annual reading at 210284000.0 for FY2024, 59.09% down from the prior year.
  • Cash from Operations for Q3 2025 was 30843000.0 at Editas Medicine, up from 50212000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 22240000.0 in Q4 2023, with the low at 57062000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 42761473.68, with a median of 42273000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 47.39% in 2023, then plummeted 128.25% in 2024.
  • Over 5 years, Cash from Operations stood at 34582000.0 in 2021, then dropped by 22.24% to 42273000.0 in 2022, then soared by 47.39% to 22240000.0 in 2023, then tumbled by 128.25% to 50762000.0 in 2024, then surged by 39.24% to 30843000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 30843000.0, 50212000.0, and 47799000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.